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Abstract
Background: Uncontrolled hypertension is the most important risk factor and leading cause of cardiovascular
diseases. It is predicted that the number of people with hypertension will increase, and a large proportion of this
increase will occur in developing countries. The highest prevalence of uncontrolled hypertension is reported in sub-
Saharan Africa, and treatment for hypertension is unacceptably low. Hypertension commonly co-exists with
comorbidities and this is associated with poorer health outcomes for patients. This review aims to estimate the
prevalence of uncontrolled hypertension among patients with comorbidities in sub-Saharan Africa.
Methods and analysis: All published and unpublished studies on the prevalence of uncontrolled hypertension
among patients with comorbidities in sub-Saharan Africa will be included. MEDLINE via OVID, Embase, and Web of
Science will be searched to identify all relevant articles published from January 2000 to June 2019. Experts in the
field will be contacted for unpublished literature, and Open SIGLE will be reviewed for relevant information. No
language restriction will be imposed. Two reviewers will select, screen, extract data, and assess the risk of bias while
a third reviewer will arbitrate the disagreements. A meta-analysis will be performed on variables that are similar
across the included studies. Proportions will be stabilized before estimates are pooled using a random effects
model. The presence of publication bias will be assessed using Egger’s test and visual inspection of the funnel
plots. This systematic and meta-analysis review protocol will be reported in accordance with the PRISMA-P protocol
guidelines. Results will be stratified by country, comorbidity, and geographic region.
Discussion: This systematic review and meta-analysis is expected to quantify the magnitude of uncontrolled
hypertension among patients with certain comorbid conditions in sub-Saharan Africa to guide policies and
interventions. This review is registered in PROSPERO International Prospective Register of Systematic reviews
CRD42019108218.
Keywords: Uncontrolled hypertension, Hypertension, Comorbidities, Sub-Saharan Africa
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Shukri.Mohamed@warwick.ac.uk
1Academic Unit of Primary Care (AUPC) and the NIHR Global Health Research
Unit on Improving Health in Slums, University of Warwick, Coventry, UK
2Health and Systems for Health Unit, African Population and Health Research
Center (APHRC), Nairobi, Kenya
Full list of author information is available at the end of the article
Mohamed et al. Systematic Reviews            (2020) 9:16 
https://doi.org/10.1186/s13643-020-1270-7
Background
Hypertension is one of the leading risk factor causing
premature death and disability adjusted life years in the
world [1]. More than a billion people in the world had
hypertension in 2015 [2] and the highest prevalence
(46%) of hypertension was in sub-Saharan Africa (SSA)
[3]. It is predicted that the number of people with hyper-
tension will increase to 1.56 billion by 2025, and a large
proportion of this increase will occur in developing
countries including SSA [4].
Uncontrolled hypertension (UHTN) in SSA is a challenge
despite increasing knowledge of hypertension care and the
availability of low-cost medications. A 2013 systematic re-
view and meta-analysis showed a very low level of treat-
ment (18%) and a high (97%) pooled prevalence of
uncontrolled hypertension in SSA [5]. High uncontrolled
rates have economic and public health implications. Mor-
bidities, such as stroke, associated with uncontrolled hyper-
tension are costly to treat and pose a burden to health care
systems in SSA that are already weak and strained [6].
At the current rate, achievement of the World Health
Organization (WHO) global target of lowering blood
pressure by 25% will be challenging to attain by 2025 in
SSA [3]. Research has shown that hypertension com-
monly co-exists with comorbidities such as chronic kid-
ney disease, diabetes, and hypercholesterolemia [7, 8].
Having comorbidities is associated with poorer health
outcomes for patients [9], and its management is com-
plex and expensive [10].
There is a dearth of literature on the impact of comor-
bidities on uncontrolled hypertension in SSA. Previous
reviews conducted in SSA have focused on hypertension
prevalence, awareness, treatment, and control [5, 11].
The last systematic review that provided an estimate for
uncontrolled hypertension in SSA was conducted in
2013 [5]. Since then, many studies have been published
and the status of uncontrolled hypertension may have
changed; thus, this update is necessary. Therefore, this
study aims to conduct a systematic review and meta-
analysis to estimate the prevalence of uncontrolled
hypertension among patients with comorbidities in sub-
Saharan Africa.
Method and analysis
Protocol registration
This review is registered in PROSPERO International
Prospective Register of Systematic reviews
(CRD42019108218) and reported according to Preferred
Reporting Items for Systematic reviews and Meta-
Analysis protocol (PRISMA-P) guidelines [12]. Add-
itional file 1 shows this in more detail.
Eligibility criteria
Inclusion criteria:
a. Types of studies: All published and unpublished
cohort or cross-sectional studies and baseline data
from randomized controlled trials conducted in
sub-Saharan Africa reporting on the prevalence of
high blood pressure/uncontrolled hypertension
while on antihypertensive treatment as primary or
secondary outcome.
b. Participants: Adults’ population with known high
blood pressure (hypertension) on any form of
antihypertensive medication with any of the
following comorbidities: Type 2 diabetes mellitus,
dyslipidemia, obesity, chronic kidney disease, stroke,
and/or transient ischemic attack, coronary heart
disease, heart failure, peripheral vascular disease,
atrial fibrillation, depression, or HIV. Study
participants should be at least 15 years of age.
Essential hypertension (also called primary or
idiopathic hypertension) will be defined in
accordance with the criteria of the Joint National
Committee (JNC) on the Prevention, Detection,
Evaluation and Treatment of High Blood Pressure
of the US National Heart, Lung and Blood Institute:
[1] persistent (seated) systolic blood pressure (SBP)
of 140 mmHg or greater or had diastolic blood
pressure 90 mmHg or greater regardless of age and
sex OR [2] hypertension deducible from the use of
antihypertensive drugs or self-reported physician-
diagnosed cases. In this study, comorbid conditions
that commonly co-exist with hypertension have
been identified from Barnett and colleagues’ article
on multi-morbidity [13].
c. Intervention(s)/exposure(s): On any form of
antihypertensive medications.
d. Outcome: Prevalence of uncontrolled hypertension
among people who report taking antihypertensive
treatment and have a comorbid condition/s (Table
1).
e. Settings: Hospital and community based studies.
f. Publication date: January 1, 2000, to June 2019.
g. Language: No language restriction.
Exclusion criteria:
a. Studies not performed in humans.
b. Reviews, commentaries, editorials, letters, and
studies without primary data or explicit description
of methods, or both.
c. Studies only reporting on uncontrolled
hypertension but not among patients with the
comorbidities of interest.
d. Qualitative studies.
e. Studies that lack relevant data needed to compute
the prevalence of uncontrolled hypertension.
f. Studies on pregnancy related hypertension
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g. Studies in children and adolescent < 15 years.
Information sources
The following major electronic databases, MEDLINE via
OVID, Excerpta Medica Database (Embase), and Web of
Science will be searched to identify all relevant articles
published from January 1, 2000, to June 15, 2019. Fur-
ther, the reference list of all relevant articles and reviews
identified through the search will be scanned to identify
additional articles. Unpublished literature will be sought
from experts in the field while grey literature such as re-
ports will also be reviewed for relevant information from
OpenSIGLE and other organizational websites such as
WHO.
Search strategy
The literature search strategy has been developed using
the medical subject headings (MeSH), BOOLEAN oper-
ator, and key text words such as “uncontrolled hyperten-
sion” OR “hypertension” AND “list of comorbidites,”
AND “sub-Saharan Africa.” To ensure maximum sensi-
tivity and precise searches for relevant information, we
will add filters such as “Africa South of the Sahara.”
A specific search strategy has been developed with
guidance from a librarian with expertise in systematic
review searching. The MEDLINE (OVID) search strategy
will be adapted to match the syntax and subject headings
for the other databases. The search strategy for MED-
LINE (OVID), Embase, and Web of Science are dis-
played in Additional file 2.
Study records
Data management
Based on the inclusion and exclusion criteria, a tool has
been developed a priori to guide the screening and selec-
tion process. The tool will be piloted and revised before
data extraction begins. The search results will be first
uploaded to EndNote software first to remove dupli-
cates. The remaining articles will be placed on Rayyan, a
mobile and a web-based software program that facilitates
the collaboration among the reviewers involved in the
screening and selection of studies to be included in the
review [14].
Selection process
Once data are obtained, two investigators will independ-
ently screen the titles and abstracts of articles retrieved
from the literature search against the inclusion criteria.
Full texts for the eligible titles and/or abstracts including
those where there is uncertainty will be obtained for fur-
ther assessment on whether to include in the study or
not. Where necessary, authors will be contacted for add-
itional information to confirm eligibility of studies. Dis-
agreements will be resolved through discussion and
when needed there will be arbitration by a third re-
viewer. Reasons for excluding articles will be recorded.
Data collection process
Data will be extracted using a standardized data extrac-
tion form. From the studies included, two assessors will
independently extract data using the predefined stan-
dardized extraction form. Disagreements will be resolved
through discussion and when needed there will be arbi-
tration by a third reviewer.
Where there is missing information, the corre-
sponding author of the study will be contacted to
request the missing information. A maximum of three
emails will be sent to the corresponding author to re-
quest for additional information before excluding the
study. For studies appearing in more than one pub-
lished article, we will consider the most recent, com-
prehensive, and with the largest sample size. For
surveys appearing in one article with multiple surveys
conducted at different time points, we shall treat each
survey as a separate study. For studies that are multi-
national, data will be separated to show the estimate
at country level.
Data items
Data on general information, authors, year, country, and
region (Eastern, Western, and Central and Southern Af-
rica), type of publication, study characteristics (study de-
sign, setting, sample size, response rate, mean or median
age, or age range), data on blood pressure measurements,
cut-offs for hypertension used, data on diagnosis of hyper-
tension, information on use of antihypertensive medica-
tion/therapy, and prevalence estimates of uncontrolled
hypertension among those on treatment will be extracted.
Where antihypertensive treatment or prevalence informa-
tion relevant for estimating uncontrolled hypertension
among those on treatment are not available, we will
Table 1 List of 11 conditions included as comorbidity
Conditions
1 Diabetes
2 Hypercholesterolemia/dyslipidemia/hyperlipidemia/
hypertriglyceridemia
3 Obesity
4 Chronic kidney disease
5 Stroke and or transient ischemic attack
6 Coronary heart disease
7 Heart failure
8 Peripheral vascular disease
9 Atrial fibrillation
10 Depression
11 HIV
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contact the corresponding author of the study to request
the missing information. The prevalence of uncontrolled
hypertension will be estimated as a percentage of all the
participants on treatment with an antihypertensive.
Outcomes and prioritization
The primary outcome is the prevalence of uncontrolled
hypertension among people who report taking antihy-
pertensive treatment and have a comorbid condition/s in
SSA.
Risk of bias in individual studies
To assess the risk of bias and quality of studies included
in this review, a tool developed by Hoy et al. for preva-
lence studies will be used [15] (see Additional file 3).
The tool contains 11 items; items 1–4 assess the external
validity, 5–10 assess the internal validity, and item 11 is
a summary of the overall risk by the reviewer based on
the responses of the above 10 items which are scored 1
if yes and 0 if no. Studies will be classified as having a
low (> 8), moderate [6–8], or high (≤ 5) risk of bias. This
exercise will be done by two reviewers and disagree-
ments will be solved by discussion and where necessary
by arbitration involving a third reviewer/author.
For each included study, we will estimate the precision
(C) or margin of error, considering the sample size (SS)
and the observed prevalence (p) of uncontrolled hyper-
tension from the formula:
SS ¼ Z2p 1−pð Þ=C2 ð1Þ
where Z was the z value fixed at 1.96 across studies
(corresponding to 95% confidence interval). The desir-
able margin of error is 5% (0.05) or lower.
Data synthesis
Crude numerators and denominators from the individ-
ual studies will be used to recalculate the study-specific
prevalence. Prevalence estimates will be summarized by
geographic regions and by comorbidities.
A meta-analysis will be performed on variables that
are similar across the included studies. Proportions will
be stabilized using the double arcsine transformation
[16], and then, a random effects meta-analysis will be
performed [17] to determine the pooled estimate of the
prevalence of uncontrolled hypertension among patients
with comorbid conditions while on treatment across
studies in SSA.
Heterogeneity will be explored using Cochrane’s Q
and quantified by I2 statistics [18]. Subgroup analyses
will be performed based on the following: patient char-
acteristics (age categories, sex, education level, socio-
economic status), patient comorbidities (diabetes, obes-
ity, chronic kidney disease among others), study design,
study setting (hospital vs community), frequently used
hypertension cut-offs, regions (Eastern, Western, and
Central and Southern Africa), and by Gross National In-
come (GNI) will be performed to identify the possible
sources of heterogeneity. The definitions of the comor-
bidities of interest will be collected, and those with the
same definitions will be analyzed together.
The presence of publication bias will be assessed using
Egger’s test and funnel plots [19]. P value < 0.10 on the
Egger’s test will be considered to be statistically signifi-
cant for publication bias. Inter-rater agreements between
the researchers involved in study selection and those in-
volved in identification of risk of bias will be assessed
using κ Cohen’s coefficient [20].
All analyses will be performed using “metaprop” rou-
tine using Stata version 15 for Windows [21]. Results
will be reported as proportions with corresponding 95%
confidence intervals (CIs).
Discussion
This review will be published in accordance with the
PRISMA guidelines [22]. The PRISMA flow diagram will
be used to record the different phases of the review
process [22]. Summary tables will be used to display the
data on distribution of uncontrolled hypertension at re-
gional level by variables of interest such as gender, resi-
dence, setting, and person level characteristics. Funnel
plots will be used to visualize publication bias of the in-
cluded studies. Forest plots will display the prevalence
estimates of uncontrolled hypertension for the included
studies as an overall pooled estimate for SSA. Results
from this review will inform healthcare providers on the
burden of co-existence of UHTN and comorbidities,
hence providing evidence that will inform the required
changes needed in clinical practice that will support
healthcare services in line with patients’ needs. Findings
from this review will be shared in conferences, peer re-
view journals, and on social media platforms.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-1270-7.
Additional file 1:. PRISMA-P checklist
Additional file 2:. Search strategy
Additional file 3:. Assessment of risk of bias template
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